- Home
- MRBK vs BDTX Comparison
MRBK vs BDTX Comparison
Compare MRBK & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRBK
- BDTX
- Stock Information
- Founded
- MRBK 2004
- BDTX 2014
- Country
- MRBK United States
- BDTX United States
- Employees
- MRBK N/A
- BDTX N/A
- Industry
- MRBK Major Banks
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MRBK Finance
- BDTX Health Care
- Exchange
- MRBK Nasdaq
- BDTX Nasdaq
- Market Cap
- MRBK 177.5M
- BDTX 181.4M
- IPO Year
- MRBK 2017
- BDTX 2020
- Fundamental
- Price
- MRBK $15.68
- BDTX $3.16
- Analyst Decision
- MRBK Buy
- BDTX Strong Buy
- Analyst Count
- MRBK 2
- BDTX 6
- Target Price
- MRBK $17.50
- BDTX $12.50
- AVG Volume (30 Days)
- MRBK 74.2K
- BDTX 840.0K
- Earning Date
- MRBK 10-23-2025
- BDTX 11-04-2025
- Dividend Yield
- MRBK 3.23%
- BDTX N/A
- EPS Growth
- MRBK 69.83
- BDTX N/A
- EPS
- MRBK 1.61
- BDTX 0.25
- Revenue
- MRBK $106,330,000.00
- BDTX $70,000,000.00
- Revenue This Year
- MRBK $25.14
- BDTX N/A
- Revenue Next Year
- MRBK $8.08
- BDTX N/A
- P/E Ratio
- MRBK $9.65
- BDTX $12.78
- Revenue Growth
- MRBK 17.11
- BDTX N/A
- 52 Week Low
- MRBK $11.16
- BDTX $1.20
- 52 Week High
- MRBK $17.33
- BDTX $6.23
- Technical
- Relative Strength Index (RSI)
- MRBK 59.19
- BDTX 58.90
- Support Level
- MRBK $15.13
- BDTX $3.13
- Resistance Level
- MRBK $15.64
- BDTX $3.43
- Average True Range (ATR)
- MRBK 0.26
- BDTX 0.18
- MACD
- MRBK -0.05
- BDTX 0.02
- Stochastic Oscillator
- MRBK 68.75
- BDTX 63.51
About MRBK Meridian Corporation
Meridian Corp is a bank holding company. Through its banking subsidiary, it operates as a full-service, state-chartered commercial bank providing personal, business lending, and deposit services. It operates in three reportable segments including Bank, Wealth, and Mortgage. The company generates maximum revenue from the Bank segment which consists of commercial and retail banking. It generates interest income from its lending (including leasing) and investing activities and is dependent on the gathering of lower-cost deposits from its branch network or borrowed funds from other sources for funding its loans.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.